Comparably to those studies, the main side effect was grade 3 and 4 neutropenia, but the incidence was considerably lower in our trial (present trial: 16.7, 0% febrile neutropenia vs literature: 42 48%, up to 11% febrile neutropenia).
In the present trial, our data support linkage between protein S-glutathionylation and DNA damage in buccal cells.
Prior to the present trial, our experimental studies in nonclinical samples had demonstrated increased positive affect as an outcome of imagery CBM, compared with a control condition (Holmes, Coughtrey, & Connor, 2008; Holmes et al., 2006; Holmes, Lang, & Shah, 2009; Nelis et al., 2012; Pictet et al., 2011; Rohrbacher, Blackwell, Holmes, & Reinecke, 2014).
A number of studies have been carried out before our decision to run the present trial.
The present trial contradicted our initial hypothesis that OPV0 was associated with higher male mortality [ 24].
In particular, the present trial confirms our previous observation (Tibaldi et al, 2006) that a modified schedule of docetaxel (37.5 mg m−2 on days 1 and 8 every 3 weeks) is feasible and well tolerated in elderly advanced NSCLC patients.
The main limitation of the present trial is the relatively small number of critically ill patients included in our trial prone to type II errors.
In our previous experiences we neither registered side-effects prospectively nor did we evaluate patient comfort in the present trial.
In addition, the data collected in the present trial do not allow for investigation of the mechanism of action for this intervention.
The panel on the right depicts the micro PC used to present trial information to the participant.
